Иринотекан Булгермед

Иринотекан Булгермед is a chemotherapy medication used to treat cancer. It belongs to the topoisomerase I inhibitor class and is administered intravenously. This EU-sourced generic provides a targeted approach for managing certain solid tumors. Suitable for patients requiring irinotecan-based regimens.

Irinotecan hydrochloride trihydrate is primarily used to treat colorectal cancer, both as a first-line therapy and in metastatic cases. It may also be prescribed for other solid tumors when recommended by a healthcare provider. This medication works by interfering with cancer cell DNA replication. Patients often ask, 'what is irinotecan used for' in the context of advanced cancer treatment.

Irinotecan may cause temporary changes in blood cell counts, leading to increased infection risk or fatigue. Some patients experience digestive effects like nausea or diarrhea shortly after administration. These effects vary by individual and are typically monitored during treatment. Hair thinning is another possible temporary effect.

This medication should only be handled and administered by healthcare professionals in a clinical setting. Patients must report any signs of infection, unusual bleeding, or severe diarrhea immediately. Regular blood tests are necessary to monitor for side effects. Avoid close contact with others who are sick during treatment.

Irinotecan may interact with other medications that affect liver enzymes, such as certain antifungals or anticonvulsants. Alcohol and grapefruit products should be avoided during treatment. Patients should inform their doctor about all prescription, over-the-counter, and herbal supplements. Some interactions may increase side effects or reduce effectiveness.